|
Name |
(1R,3S,4R,7R,8S,12S)-3,4,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.01,10.03,8]heptadec-5-ene-11,16-dione
|
| Molecular Formula | C20H22N2O9S2 | |
| IUPAC Name* |
(1R,3S,4R,7R,8S,12S)-3,4,7-trihydroxy-13-(2-hydroxy-3,4-dimethoxyphenyl)-9-oxa-14,15-dithia-10,17-diazatetracyclo[10.3.2.01,10.03,8]heptadec-5-ene-11,16-dione
|
|
| SMILES |
COC1=C(C(=C(C=C1)C2[C@@H]3C(=O)N4[C@@](C[C@@]5([C@@H](C=C[C@H]([C@@H]5O4)O)O)O)(C(=O)N3)SS2)O)OC
|
|
| InChI |
InChI=1S/C20H22N2O9S2/c1-29-10-5-3-8(13(25)14(10)30-2)15-12-17(26)22-20(33-32-15,18(27)21-12)7-19(28)11(24)6-4-9(23)16(19)31-22/h3-6,9,11-12,15-16,23-25,28H,7H2,1-2H3,(H,21,27)/t9-,11-,12-,15?,16+,19+,20-/m1/s1
|
|
| InChIKey |
PPQRKKLHNNMQJV-GHYZKQQQSA-N
|
|
| Synonyms |
Pretrichodermamide A
|
|
| CAS | NA | |
| PubChem CID | 139585503 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 498.5 | ALogp: | -1.2 |
| HBD: | 5 | HBA: | 11 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 209.0 | Aromatic Rings: | 6 |
| Heavy Atoms: | 33 | QED Weighted: | 0.283 |
| Caco-2 Permeability: | -5.982 | MDCK Permeability: | 0.00000752 |
| Pgp-inhibitor: | 0.081 | Pgp-substrate: | 0.588 |
| Human Intestinal Absorption (HIA): | 0.746 | 20% Bioavailability (F20%): | 0.754 |
| 30% Bioavailability (F30%): | 0.985 |
| Blood-Brain-Barrier Penetration (BBB): | 0.189 | Plasma Protein Binding (PPB): | 78.73% |
| Volume Distribution (VD): | 0.626 | Fu: | 10.70% |
| CYP1A2-inhibitor: | 0.022 | CYP1A2-substrate: | 0.481 |
| CYP2C19-inhibitor: | 0.088 | CYP2C19-substrate: | 0.506 |
| CYP2C9-inhibitor: | 0.251 | CYP2C9-substrate: | 0.766 |
| CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.183 |
| CYP3A4-inhibitor: | 0.39 | CYP3A4-substrate: | 0.606 |
| Clearance (CL): | 4.836 | Half-life (T1/2): | 0.703 |
| hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.132 |
| Drug-inuced Liver Injury (DILI): | 0.966 | AMES Toxicity: | 0.386 |
| Rat Oral Acute Toxicity: | 0.383 | Maximum Recommended Daily Dose: | 0.056 |
| Skin Sensitization: | 0.15 | Carcinogencity: | 0.83 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.848 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC006030 | ![]() |
0.802 | D03DIG | ![]() |
0.283 | ||
| ENC003545 | ![]() |
0.609 | D0L1JW | ![]() |
0.257 | ||
| ENC003540 | ![]() |
0.580 | D01XWG | ![]() |
0.252 | ||
| ENC004276 | ![]() |
0.553 | D06GCK | ![]() |
0.250 | ||
| ENC003738 | ![]() |
0.538 | D0C9XJ | ![]() |
0.247 | ||
| ENC003544 | ![]() |
0.529 | D07VLY | ![]() |
0.247 | ||
| ENC003539 | ![]() |
0.500 | D04TDQ | ![]() |
0.239 | ||
| ENC004279 | ![]() |
0.455 | D0WE3O | ![]() |
0.238 | ||
| ENC004278 | ![]() |
0.455 | D0D4HN | ![]() |
0.231 | ||
| ENC004281 | ![]() |
0.455 | D06TQZ | ![]() |
0.229 | ||